Xechem Recieves NIH Grant For Anti-Sickling Agent
Xechem International (XKEM.OB)announced today it had recieved a grant from the NIH totalling more than $470,000 U.S. to study the toxicity of 5-HMF.
The company had purchased the rights to the compound from Virginia Commonwealth University (VCU) back in December of 2005, and in May of 2006 the FDA designated the compound Orphan Drug Status.
5-HMF is a natural compound that has been shown to exhibit great anti-sickling potential. It shows great affinity for sickled hemoglobin cells, and does not attack or bind any other proteins.
Xechem already develops and markets NICOSAN, a natural anti-sickling agent in Nigeria.
Shares of Xechem closed at $0.0258, trading over the counter.
_
Xechem International (XKEM.OB)announced today it had recieved a grant from the NIH totalling more than $470,000 U.S. to study the toxicity of 5-HMF.
The company had purchased the rights to the compound from Virginia Commonwealth University (VCU) back in December of 2005, and in May of 2006 the FDA designated the compound Orphan Drug Status.
5-HMF is a natural compound that has been shown to exhibit great anti-sickling potential. It shows great affinity for sickled hemoglobin cells, and does not attack or bind any other proteins.
Xechem already develops and markets NICOSAN, a natural anti-sickling agent in Nigeria.
Shares of Xechem closed at $0.0258, trading over the counter.
_
posted by Nico at
7:27 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home